Investig Clin Urol.  2017 Mar;58(2):79-81. 10.4111/icu.2017.58.2.79.

Regenerative pharmacology in urology

• Andersson
• Williams J

• KMID: 2368471
• DOI: http://doi.org/10.4111/icu.2017.58.2.79

Abstract

No abstract available.

MeSH Terms

Pharmacology*
Urology*

Reference

1. Andersson KE, Christ GJ. Regenerative pharmacology: the future is now. Mol Interv. 2007; 7:79–86.

2. Christ GJ, Saul JM, Furth ME, Andersson KE. The pharmacology of regenerative medicine. Pharmacol Rev. 2013; 65:1091–1133.

3. Williams JK, Andersson KE. Regenerative pharmacology: recent developments and future perspectives. Regen Med. 2016; 11:859–870.

4. Tran C, Damaser MS. Stem cells as drug delivery methods: application of stem cell secretome for regeneration. Adv Drug Deliv Rev. 2015; 82-83:1–11.

5. Evans RJ, Moldwin RM, Cossons N, Darekar A, Mills IW, Scholfield D. Proof of concept trial of tanezumab for the treatment of symptoms associated with interstitial cystitis. J Urol. 2011; 185:1716–1721.

6. Schneider MP, Schwab ME, Kessler TM. Anti-Nogo-A antibody: a treatment option for neurogenic lower urinary tract dysfunction? BJU Int. 2015; 115:Suppl 6. 16–17.

7. Williams JK, Dean A, Badlani G, Andersson KE. Regenerative medicine therapies for stress urinary incontinence. J Urol. 2016; 196:1619–1626.

8. Schwab ME, Strittmatter SM. Nogo limits neural plasticity and recovery from injury. Curr Opin Neurobiol. 2014; 27:53–60.